📊 BRTX Key Takeaways
Is BioRestorative Therapies, Inc. (BRTX) a Good Investment?
BioRestorative Therapies is in severe financial distress with only $23.2K quarterly revenue and $3.4M operating losses, creating a deteriorating cash position with less than one year of runway at current burn rates. Net income losses are accelerating (down 58.6% YoY) and the company shows no visible path to profitability or operational cash flow breakeven. While positive gross margin suggests product viability, the company faces existential going-concern risks without significant capital infusion.
BioRestorative Therapies shows extremely weak fundamentals, with minimal revenue, deeply negative operating and net margins, and heavy cash burn relative to its asset base and cash position. While gross margin is high and leverage is low, the business currently lacks evidence of scalable commercialization and appears dependent on external financing to sustain operations.
BioRestorative Therapies, Inc. Key Strengths (BRTX)
- Positive gross margin of 68.1% indicates products have economic viability when sold
- Low debt burden (0.08x D/E ratio) provides financial flexibility without leverage constraints
- Revenue growing 32.9% YoY demonstrates some market traction despite microscopic absolute base
- High gross margin indicates the limited revenue base is not constrained by direct production costs
- Balance sheet leverage is low, with modest long-term debt relative to equity
- Current and quick ratios above 1.0 suggest near-term liquidity is not yet fully impaired
BRTX Stock Risks: BioRestorative Therapies, Inc. Investment Risks
- Catastrophic cash burn of -$3.9M quarterly free cash flow with only $3.1M cash on hand yields less than one year of operating runway
- Accelerating losses: net income down 58.6% YoY while operating losses remain at $3.4M against $23.2K revenue
- Zero insider Form 4 filings in 90 days and negative interest coverage of -32.4x indicate management lacks confidence and company cannot service debt from operations
- Revenue declined 35.7% year over year, indicating weak and deteriorating commercial traction
- Operating loss of $11.82M and free cash flow of -$8.41M are far too large relative to $602.44K cash on hand
- Very negative ROE and ROA indicate severe capital inefficiency and ongoing shareholder dilution risk if funding is needed
Key Metrics to Watch
- Cash runway: monitor quarterly burn rate relative to balance for going-concern assessment
- Revenue acceleration: must scale dramatically from $23.2K base to offset $3.8M operating losses
- Operating cash flow inflection: critical when OCF approaches breakeven to demonstrate path to sustainability
- Quarterly operating cash burn relative to cash balance
- Revenue growth and evidence of sustained commercialization
BioRestorative Therapies, Inc. (BRTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.35x current ratio provides a solid financial cushion.
BRTX Profit Margin, ROE & Profitability Analysis
BRTX vs Services Sector: How BioRestorative Therapies, Inc. Compares
How BioRestorative Therapies, Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BioRestorative Therapies, Inc. Stock Overvalued? BRTX Valuation Analysis 2026
Based on fundamental analysis, BioRestorative Therapies, Inc. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BioRestorative Therapies, Inc. Balance Sheet: BRTX Debt, Cash & Liquidity
BRTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BioRestorative Therapies, Inc.'s revenue has grown significantly by 421% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.16 indicates the company is currently unprofitable.
BRTX Revenue Growth, EPS Growth & YoY Performance
BRTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $23.2K | -$2.2M | $-0.12 |
| Q3 2025 | $11.8K | -$1.1M | $-0.13 |
| Q2 2025 | $89.1K | -$2.2M | $-0.30 |
| Q1 2025 | $25.0K | -$2.2M | $-0.33 |
| Q3 2024 | $30.7K | -$1.1M | $-0.13 |
| Q2 2024 | $64.5K | -$2.2M | $-0.50 |
| Q1 2024 | $31.3K | -$2.2M | $-0.33 |
| Q3 2023 | $29.0K | -$2.9M | $-0.64 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BioRestorative Therapies, Inc. Dividends, Buybacks & Capital Allocation
BRTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BioRestorative Therapies, Inc. (CIK: 0001505497)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BRTX
What is the AI rating for BRTX?
BioRestorative Therapies, Inc. (BRTX) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BRTX's key strengths?
Claude: Positive gross margin of 68.1% indicates products have economic viability when sold. Low debt burden (0.08x D/E ratio) provides financial flexibility without leverage constraints. ChatGPT: High gross margin indicates the limited revenue base is not constrained by direct production costs. Balance sheet leverage is low, with modest long-term debt relative to equity.
What are the risks of investing in BRTX?
Claude: Catastrophic cash burn of -$3.9M quarterly free cash flow with only $3.1M cash on hand yields less than one year of operating runway. Accelerating losses: net income down 58.6% YoY while operating losses remain at $3.4M against $23.2K revenue. ChatGPT: Revenue declined 35.7% year over year, indicating weak and deteriorating commercial traction. Operating loss of $11.82M and free cash flow of -$8.41M are far too large relative to $602.44K cash on hand.
What is BRTX's revenue and growth?
BioRestorative Therapies, Inc. reported revenue of $23.2K.
Does BRTX pay dividends?
BioRestorative Therapies, Inc. does not currently pay dividends.
Where can I find BRTX SEC filings?
Official SEC filings for BioRestorative Therapies, Inc. (CIK: 0001505497) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BRTX's EPS?
BioRestorative Therapies, Inc. has a diluted EPS of $-0.12.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BRTX's fundamental grade?
Based on our AI fundamental analysis in June 2026, BioRestorative Therapies, Inc. has a D grade with 96% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BRTX stock overvalued or undervalued?
Valuation metrics for BRTX: ROE of -71.2% (sector avg: 16%), net margin of -9,298.3% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
What is BRTX's AI grade for 2026?
Our dual AI analysis gives BioRestorative Therapies, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BRTX's free cash flow?
BioRestorative Therapies, Inc.'s operating cash flow is $-3.8M, with capital expenditures of $116.1K. FCF margin is -16,935.1%.
How does BRTX compare to other Services stocks?
Vs Services sector averages: Net margin -9,298.3% (avg: 10%), ROE -71.2% (avg: 16%), current ratio 2.35 (avg: 1.5).